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Abstract 
As Schistosoma mansoni worms inhabit the portal triad of infected hosts, deleterious changes 
were encountered in the blood picture. The aim of the study is to explore the damaging 
hematological effects due to S.mansoni infection in albino mice before and after treatment 
with either Commiphora molmol extract or Praziquantel. Seventy two albino mice were 
recruited in this study and divided into 4 groups of 18 mice each, 54 of them were infected 
with S.mansoni cercariae.7 weeks post-infection, infected animals were treated with 500 
mg/kg either as a single dose for 2 days in Praziquantel or for 5 consecutive days in 
Commiphora molmol extract. Blood samples were collected at 1, 2 and 4 weeks after 
treatment for assessment of complete blood counts (Hb, erythrocytes count, haematocrite 
value, MCV, MCH, MCHC, Platelet count, leucocytic count and differential leucocytic 
counts).S.mansoni infection resulted in multiple damaging effects of the blood profile on 
infected non-treated hosts as evidenced by decrease in red blood cells and platelets and rise 
in white cells with the advance of infection. Treatment with Praziquantel corrected the blood 
profile of erythrogram and the platelet count in progressive manner with advance of time after 
treatment more than Commiphora molmol Extract. This study declared that Praziquantel and 
Commiphora molmol extract were safe drugs without dverse hematological effects on infected 
treated mice with more ameliorative action achieved by Praziquantel than Commiphora 
molmol extract. 
Keywords: Blood picture, Mice, Mirazid, Praziquantel, Schistosoma. 
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INTRODUCTION 
Schistosomiasis is one of the most widespread of the 
major parasitic diseases and its negative socio-economic 
and public health impact in tropical and subtropical regions 
of the world (WHO, 2007). Morbidity due to S.mansoni 
infection is mainly as a result of the host’s responses to 
schistosome egg antigens to form granulomas mainly in 
the intestines and the liver where the eggs are trapped 
(Bindseli et al., 2004).The significant health problems 
associated with schistosomiasis include impaired cognitive 
potential among primary school-age children, 
hepatosplenomegaly, anaemia, bladder cancer and stunted 
growth (Midzi et al., 2008). Also, genital schistosomiasis, 
which manifests at reproductive age if schistosomiasis is 
not treated, is attributed as a risk factor for HIV 
transmission (Feldmeier et al., 1994).The national policy on 
schistosomiasis control has adopted Praziquantel as the 
main drug of use to reduce morbidity. It is widely preferred 
owing to its safety, present low cost, accepted single dose 
with improved patient compliance, and efficacy against all 
five schistosome species (Deribew et al., 2013). About 66.5 
million individuals infected with schistosomiasis (53.2 
million school-aged children and 13.3 million adults) in 52 
countries all-over the world mostly in African countries 
received PZQ treatment in 2015 (WHO, 2016). 
Pharco Pharmaceuticals (Alexandria, Egypt) registered 
a drug under the name of (Mirazid, MZD) in 29 January 
2002, as new innovative drug of natural origin for treatment 
of schistosomiasis in the form of soft gelatin capsule 
containing 300 mg of purified Commiphora molmol extract 
(myrrh) based on its effectiveness through many clinical 
and field studies delivered to the Egyptian ministry of 
health-drug policy planning center (Al-Kazzaz et al., 2017). 
In previous studies, the drug showed potent 
antischistosomal activity as well as high safety profile on 
biochemical parameters but lower than PZQ (Al-Kazzaz et 
al., 2016; Al-Kazzaz et al., 2017a; Al-Kazzaz et al., 2017b; 
Aziz et al., 2017). The Baseline data about the 
hematological effects of schistosomiasis or its treatment 
with PZQ or MZD are scarcely available in the literature. 
This prompted us to study the hematological parameters in 
a murine model under the effect of schistosomiasis and its 
treatment with MZD in comparison with PZQ. 
                               
MATERIALS AND METHODS 
This study was conducted in September 2014 and 
ended in January 2015.   
 
MATERIALS  
-Seventy two albino mice were brought from 
Safepharma research laboratory, New Borg El-Arab City, 
Alexandria, Egypt. 
-Biomophalaria alexandrina snails infected with 
S.mansoni miracidia were purchased from Theodore 
Bilharz Research Institute, Cairo; Egypt.  
-Praziquantel tablets (Batch No: 9118014) were 
purchased from a local pharmacy and Mirazid capsules 
(Batch No: 296) were obtained from Pharco 
Pharmaceuticals.  
 
METHODS  
Mice infection  
Each mouse was infected with 100 S.mansoni 
cercariae by body immersion (Smithers and Terry, 
1965).The S.mansoni cercariae were shedded from 
infected B.alexandrina snails after their exposure to 
flourecent light for about 1 hr then counted on a glass slide 
(Liang et al., 1987).
 
Mice were examined at 45 days after 
cercarial infection to investigate the presence of S.mansoni 
eggs in the stool (Khalil, 2000). 
Study design 
Mice were acclimatized for 1 week before test and only 
healthy animals were assigned to the present study. The 
drugs were administered after overnight fasting and eating 
was allowed after one hour. Treatment started 50 days’ 
post infection. The study was carried out on 4 groups of 18 
infected mice each. G1 was normal non-treated non-
infected control group. G2 was non-treated infected control 
group. G3 was given PZQ (500 mg/kg for 2 days (Bakr et 
al., 2009). G4 was given MZD (500 mg/kg for 5 days) 
(Massoud et al., 2000). The animals were housed in a 
room with a controlled adequate environmental 
temperature (20 ±1
0
C), a relative humidity (50%-60%),12 
light-dark cycles, and ventilation (more than 15 times/h). 
Mice were housed in separate cages and allowed free 
access to water and food according to the NRC guidelines 
(NRC, 2011). 
Evaluation of the Hematological Parameters  
Blood samples were withdrawn before sacrification of 
mice using capillary tubes introduced into the medial retro-
orbital venous plexus, a part of blood (about 300 ul) was 
collected into vacutainer tubes containing an anticoagulant 
(EDTA)] for determination of Complete Blood Count (CBC) 
(Sewify, 2009; Lewis et al., 2006) by using haematology 
fully-automated cell counter (Mindray BC-3200). 
Ethical considerations 
The study protocol was reviewed and approved by the 
ethics committee of the medical research institute (MRI), 
University of Alexandria in October, 2014. 
Statistical analysis  
The data were coded, collected and analyzed using 
the independent two-sample t-test using Minitab statistical 
software, version 14 (Minitab Inc, Pennsylvania State 
College, Pennsylvania, USA). Descriptive statistics were 
expressed as arithmetic mean ± SD as measures of central 
tendency and dispersion, respectively. The level of 
significance (P<0.05) was considered statistically 
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significant. Fisher's exact test was used to compare the 
difference in proportions between Mirazid and Praziquantel. 
                               
RESULTS AND DISCUSSION 
Data presented in Table 1 showed that S.mansoni-
infected mice presented with highly significant and 
progressive decrease (13%, 26.8% and 30.8%) in RBCs 
count, (27.5%, 46.6%, 59.4%) in the haemoglobin level and 
21.6%,35.6% and 41.7% in the haematocrit value (HCT) in 
infected non-treated mice at 8,9 and 11 WPI respectively 
as compared to the non-treated mice. as well as 
progressive decrease in red blood cell indices (9.7%, 
12.8% and 25% in the MCV, 16.8%, 27.14% and 47.88% 
in the MCH and 7.5%, 17.2% and 30.33% in the MCHC at 
8, 9 and 11 WPI as compared to the non-treated mice. 
Treatment with PZQ resulted in progressive increase in the 
RBCs count (4%,16.9% and 12.9%), HB level (11.9%,57% 
and 107.6%), HCT% (12.5%,40.1% and 42.5%), red blood 
cell indices [MCV (3.2%,20% and 26.2%), MCH 
(7.3%,34.12% and 83.9%) at 1,2 and 4 WPT and MCHC 
(12% and 45.7%) at 2 and 4 WPT, respectively as 
compared to the infected non-treated mice (Table 1).  
 
 
Table 1. Erythrocytes and their related indices in S. mansoni-infected mice under different treatments at different follow up 
periods. 
Parameter 
/Group 
WPT Normal Infected                                            
Non-treated 
PZQ MZD 
HB (g/dl) 1 12.70±0.57 9.20±0.77A [-27.5%] 10.30±0.44b (+11.9%) 9.54±0.35  (+3.6%) 
2 13.26±1.00 7.07±0.90A [-46.6%] 11.10±0.61B (+57%) 10.25±1.0B (+44.9%) 
4 14.12±1.69 5.73±0.36A [-59.4%] 11.90±0.61B (+107.6%) 11.37±1.11B (+98.4%) 
RBCs (10
6
 Cell/ul) 1 8.05±0.14 7.00±0.23A [-13%] 7.28±0.60 (+4%) 7.10±0.07 (+1.4%) 
2 8.20±0.48 6.00±0.27A [-26.8%] 7.00±0.67b (+16.9%) 6.90±0.73b (+15%) 
4 8.96±0.63 6.20±0.53A [-30.8%] 7.00±0.01b (+12.9%) 6.90±0.22b (+11%) 
PCV (%) 1 40.82±1.30 32.00±3.21A [-21.6%] 36.00±1.81b (+12.5%) 32.00±1.15 (0%) 
2 42.40±1.95 27.30±2.60A [-35.6%] 38.27±1.12B (+40.1%) 31.00±2.55b (+13.5%) 
4 50.98±3.04 29.70±2.03A [-41.7%] 42.33±2.52B (+42.5%) 40.10±2.03B (+35%) 
MCV (fl) 1 50.83±3.59 45.70±3.66a [-9.7%] 47.20±.02 (+3.2%) 45.00±2.55 (-1.5%) 
2 52.21±3.00 45.50±4.06a [-12.85%] 54.60±2.53B (+20%) 44.90±2.12 (-1.3%) 
4 64.04±3.68 47.90±4.10A [-25%] 60.47±2.03B (+26.2%) 52.70±2.57b (+10%) 
MCH (pg) 
 
1 15.81±0.61 13.14±1.02A [-16.8%] 14.10±1.05 (+7.3%) 13.40±0.81 (+1.9%) 
2 16.17±0.56 11.78±0.70A [27.14%] 15.80±1.46B (+34.12%) 14.80±0.57B (+25.6%) 
4 17.73±0.70 9.24±0.55A [-47.88%] 17.00±1.00B (+83.9%) 16.40±0.84B (+61.2%) 
MCHC (%) 1 31.11±2.57 28.75±3.32 [-7.5%] 28.60±1.98 (-0.5%) 29.80±1.73 (+3.6%) 
2 31.27±1.85 25.89±2.07A [-17.2%] 29.00±1.86b (+12%) 33.00±1.58B (+27.4%) 
4 27.69±1.84 19.29±1.56A [-30.33%] 28.11±1.42B (+45.7%) 28.30±1.40B (+46.7%) 
The statistical test used was independent two-sample t-test. Values were expressed as mean ± SD. Numbers in parentheses 
indicate the percentage change, Numbers in parentheses [  ] indicate the percentage of change in relation to non- infected non-
treated mice and Numbers in parentheses ( ) indicate the percentage of change in relation to infected non-treated. a: Statistically 
significant at P < 0.05 compared to non-infected, A: highly significant at P < 0.01compared to non-infected, b : Statistically 
significant at P < 0.05 compared to non-treated , B: highly significant at P < 0.01 compared to non-treated. 
 
 
In the current study, infected mice showed significant 
elevation in WBC's counts (Leukocytosis) in a rate of 
46.9% and 101.2% at 9 and 11 WPI respectively). Infected 
non-treated group revealed progressive lymphocytosis in 
relation to the time of infection reaching 38.8% at 4 WPI. 
Neutropenia was evident in an ascending manner in 
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response to infection in non-treated mice in a rate of 
(24%,33.3% and 62.1%) at 8,9 and 11 WPI. Monocytes 
and basophils were not significantly changed in infected 
non-treated mice at both 1,2 or 4 weeks’ post-infection. 
PZQ treatment resulted in non-significant decrease in 
WBCs count (10.8%) 1WPT but it reduced TLC 
significantly at 2 and 4 WPT, respectively in rate of (17.8% 
and 48.8%). This was accompanied by significant reduction 
of lymphocytes (31.7% and 57.9 %) at 2 and 4 WPT, 
respectively. On other hand, it increased the neutrophils 
count in high statistical significance (25.6%, 87.6% and 
287.4 %) at 1, 2 and 4 WPT, respectively and reduced 
eosinophilia in a rate reached 40.2% without significant 
effects on basophils and monocytes. MZD caused 
significant reduction in TLC (14.2% and 35.1%), in 
lymphocytes (18.2% and 42%) at 2 and 4 WPT and in 
esinophils (9% and 34.5%) but significant increase in 
neutrophils at 2 or 4 WPT (53.5% and 215.7%) (Table 2).  
In this study, S. mansoni-infected non-treated mice showed 
progressive degree of thrombocytopenia (as the platelet 
count decreased in response to time of infection in rate of 
(14.1%, 20.7% and 33.6%) at 8,9 and 11 WPI, respectively 
as compared to the non-infected non-treated control mice. 
Treatment of infected mice with PZQ and MZD caused 
significant increase in the platelet count at 2 or 4 WPT and 
the effect was higher for PZQ (31.9% and 72.1%) followed 
by MZD (25.5% and 50.4%) (Figure 1). 
 
 
Table 2. Total and Differential Leucocytic counts in S. mansoni-infected mice under different treatments at different follow up 
periods.  
Parameters /Group WPT Mice groups 
MZD PZQ Infected    Non-treated 
 
 
Non-infected 
Non-treated 
 
 
Total Leucocytes 
(10
3 
cell//ul) 
 
1 12.36±1.83 (+0.1) 11.00±1.84 (-10.8%) 12.34±2.50 (+20.7%) 10.22±1.91 
2 11.90±1.70b (-14.2%) 11.40±0.78B (-17.8%) 13.87±0.70A (+46.9%) 9.44±1.29 
4 9.17±2.15B (-35.1) 7.23±0.55B (-48.8%) 
 
14.13±0.85A (+101.2%) 7.02±0.62 
Lymphocytes (%) 1 70.00±1.20 (-1.4%) 68.80±1.77b (-3%) 71.00±3.02a (+5.1%) 67.50±0.48 
2 53.90±1.52B (-18.2%) 45.00±3.17B (-31.7%) 65.90±1.51A (+17%) 56.30±0.05 
4 40.00±1.79B (-42%) 29.00±1.13B (-57.9%) 69.00±1.53A (+38.8%) 49.70±0.71 
Neutrophils (%) 1 21.20±1.46 (+10.9%) 24.00±1.58B (+25.6%) 19.10±1.98A (-24.5%) 25.30±1.98 
2 38.70±1.90B (+53.5%) 47.30±3.61B (+87.6%) 25.20±1.15A (-33.3%) 37.80±0.39 
4 50.20±1.04B (+215.7%) 61.60±9.50B (+287.4%) 15.90±1.74A (-62.1%) 42.00±0.49 
Esinophils (%) 1 7.10±0.65b (-10.1%) 7.10±0.11b (-10.1%) 7.90±0.45A (+51.9%) 5.20±0.37 
2 6.00±0.32B (-9%) 5.60±0.25b (-15.1%) 6.60±0.68 (+83.3%) 3.60±0.28 
4 9.10±0.08B (-34.5%) 8.30±0.35B (-40.2%) 13.90±0.14 (+90.4%) 7.30±0.31 
Monocytes (%) 1 1.30±0.09 (0%) 1.40±0.03 (-7.6%) 1.30±0.20 (0%) 1.30±0.61 
2 1.90±0.07 (+5.5%) 1.80±0.26 (-5.2%) 1.90±0.03 (0%) 1.90±0.09 
4 1.10±0.06 (0%) 1.10±0.01 (-9%) 1.10±0.11 (+10%) 1.00±0.07 
Basophils (%) 
 
 
1 0.4±0.01 (-42.8%) 0.70±0.05 (-14.2%) 0.70±0.01 (0%) 0.70±0.01 
2 0.30±0.02 (-42.8%) 0.30±0.01 (-25%) 0.40±0.01 (0%) 0.40±0.01 
4 0.00±0.02 (0%) 0.00±0.00 (0%) 0.00±0.00 (0%) 0.00±0.00 
The statistical test used was independent two-sample t-test. Values were expressed as mean ± SD. Numbers in parentheses indicate the 
percentage change.  a: Statistically significant at P < 0.05 compared to non-infected. A: highly significant at P < 0.01compared to non-
infected. b: Statistically significant at P < 0.05 compared to non-treated. B: highly significant at P < 0.01 compared to non-treated. 
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Fig. 1. Percentage change in mean Platelet counts in S.mansoni-infected mice under MZD and PZQ treatments at different 
follow up periods. 
 
 
DISCUSSION 
Schistosomes are blood flukes that inhabit the blood 
vessels of humans, Schistosoma mansoni and S. 
japonicum live in the mesenteric venules while S. 
haematobium adults live in the veins of the vesical plexus 
(Ross et al., 2002).
 
 These parasites are exclusive blood 
feeders, and it is estimated that female S. mansoni worms 
can ingest approximately 330000 erythrocytes per hour 
and the ingested red cells are lysed in the gastrodermis to 
enable the parasites to digest hemoglobin (Don et al., 
2008).
 
RBCs provide essential nutrients for the sexual 
maturation of female S. japonicum (Wang et al., 2015).  
In this study, the count of the erythrocytes in the blood 
of schistosomiasis-infected mice showed highly significant 
and progressive decrease in the number from the 8
th
 week 
of infection till the 11
th
 week to 30.8% associated with 
decrease in haemoglobin level to 59.4% as well as the 
haematocrit value (HCT) to 41.7% as compared to the non-
treated mice. The erythrocytic indices were decreased such 
as MCV to 25%, MCH to 47.88% and MCHC to 30.33%. 
The decline in the Hb denoted evidence of anaemia as 
defined by the WHO
 
as a decrease in haemoglobin less 
than 13 g/dl in men or 12 g/dl in women) (WHO, 
2011) .Several works mostly in all schistosomes reported 
progressive decrease in the Hb, RBCs and HCT which 
indicate hypochromacia and as there was progressive 
decrease in MCV at the advance of infection especially at 
11 WPI indicating microcytosis, so this type of anemia may 
direct the etiology to iron deficiency. This cause was 
reported previously in human (Friedman et al., 2005; 
Leenstra et al., 2006; Cappellini et al., 2015) or 
experimentally infected animals (Abdel-Ghaffar and 
Qurtam, 2001; Soliman and El-Shenawy, 2003; Sewify, 
2009; Butler et al., 2012; Al-Kazzaz, 2014).  
Treatment with PZQ resulted in progressive increase 
in the RBCs count (4%,16.9% and 12.9%), HB level 
(11.9%,57% and 107.6%), HCT% (12.5%,40.1% and 
42.5%), red blood cell indices [MCV (3.2%,20% and 
26.2%), MCH (7.3%,34.12% and 83.9%) at 1,2 and 4 WPT 
and MCHC(12% and 45.7%) at 2 and 4 WPT, respectively 
as compared to the infected non-treated mice. These 
findings indicate that PZQ had no damaging effect on 
erythrocytes and their indices in S.mansoni infected mice 
as previously reported (Ahmed, 1993). MZD resulted in 
significant improvement in these parameters in the 4
th
 week 
of treatment and proved to be safe on erythrocytic 
parameters as previously reported by Massoud et al. 
(2000) who tested MZD in doses 50,100 and 200 mg/kg for 
2 months to normal rats and reported non-significant 
changes on HB, HCT and RBCs counts. Improvement in 
HB level about 14% at 3 months after MZD treatment (in 
doses 15 mg/kg for 3 days) was noticed in 49 patients 
infected with intestinal schistosomiasis (Soliman et al., 
2004; Waheeb and Abdel Hafeez, 2001). 
Currently in this work, Leukocytes showed significant 
elevation in infected mice in a rate of 46.9% and 101.2% at 
9 and 11 WPI respectively). This reported leukocytosis was 
nearly similar to the results previously reported (Soliman et 
al., 2004; Freudenstien-Dan et al., 2003; Allan et al., 2014). 
Such increase in the total leukocytes counts was attributed 
to the stimulation of the cellular production as a powerful 
defense reaction against the schistosomes and/or their ova 
(Soliman and El-Shenawy, 2003).
 
The activated leucocytes 
are known to participate in immunity to S.mansoni, where 
they attach to the parasite surface and secrete 
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schistosomicidal substances as cationic protiens, hydrolytic 
enzymes, and oxidants implicated in the damage of the 
schistosomes (Freudenstien-Dan et al., 2003). Other 
studies reported leucopenia (low WBCs) in S. mansoni-
infected mice at 8 WPI (Allam, 2009; Mahmoud and El-
Bessoumy, 2013). However, Abdel-Mottaleb et al., 2008 
reported non-significant changes in the total leucocytic 
count in S. mansoni-infected mice at 11WPI.  
In this work, infected non-treated group revealed 
progressive lymphocytosis in relation to the time of infection 
reaching 38.8% at 4 WPI. These results were in agreement 
with the results of Allan et al. (2014) and Soliman and El-
Shenawy (2003) who reported lymphocytosis at 6 or 9 WPI 
but not agree with other reports where there was 
lymphopenia ranging from 20.2 to 59.2% at 8 or 11 WPI 
(Thabet et al., 2007; Allam, 2009; Abdel-Mottaleb et al., 
2008; Mahmoud and El-Bessoumy, 2013). Neutropenia 
was evident in an ascending manner in response to 
infection in non-treated mice in a rate of (24%, 33.3% and 
62.1%) at 8,9 and 11 WPI. Variable degrees of neutrophilia 
ranging from 16.4% to 231% in S.mansoni infected mice at 
8,9 and 11 WPI were reported by others (Soliman and El-
Shenawy, 2003; Thabet et al., 2007; Allam, 2009). On the 
contrary, others reported decreased rate of neutophils 
(38.1% and 59.5%), respectively in infected non-treated 
mice at 8 or 11 WPI (Mahmoud and El-Bessoumy, 2013; 
Abdel-Mottaleb et al., 2008).  
In this study, Eosinophils flourished in non-treated 
infected mice in progress to infection time as there was 
increased rate of 51.9%, 83.3% and 90.4% at 8, 9 and 11 
WPI. Eosinophilia was reported at 8 WPI in a rate of 
238.4% and 158.3% respectively by Allam (2009) and 
Mahmoud and El-Bessoumy (2013). While, Soliman and 
El-Shenawy, 2003 observed 70% increase in the mean 
value of esinophils in infected non-treated animals at 9 
WPI. Thabet et al.,2007; Abdel-Mottaleb et al., 2008 
reported 175.4% and 415.3% increase in the level of 
esinophilic count at 11 WPI, respectively.  
The link between helminth infections and increase in 
the count of eosinophils in the blood and tissues of the host 
is well known (Reimert et al., 2006). During the acute 
infections with tissue-migrating larvae or following the 
sudden release of antigens from parasites dying either 
spontaneously or following chemotherapy is characterized 
by helminth-induced eosinophilia (O'Connell and Nutman, 
2015). 
Monocytes and basophils were not significantly 
changed in infected non-treated mice at both 1,2 or 4 
weeks post-infection as previously reported (Allam, 2009; 
Abdel-Mottaleb et al., 2008) at 8 or 11 WPI. However, 
Soliman and El-Shenawy, 2003; Mahmoud and El-
Bessoumy, 2013 reported monocytosis at 9 or 11 WPI. 
Treatment of infected mice with PZQ resulted in non-
significant decrease in WBCs count (10.8%) 1WPT but the 
drug reduced significantly TLC at 2 and 4 WPT, 
respectively in rate of (17.8% and 48.8%). This was 
accompanied by significant reduction of lymphocytes 
(31.7% and 57.9 %) at 2 and 4 WPT, respectively. 
Treatment with PZQ decreased leukocytosis significantly in 
a progressive manner from 10.8%,17.8 and 48.8% at 1, 2 
and 4 WPT, respectively. On other hand, it increased the 
neutrophils count in high statistical significance (25.6%, 
87.6% and 287.4 %) at 1, 2 and 4 WPT, respectively and 
reduced eosinophilia in a rate reached 40.2% and 
lymphocytosis to 57% at 4 WPT, respectively without 
significant effects on basophils and monocytes. MZD 
caused significant reduction in TLC (14.2% and 35.1%), in 
lymphocytes (18.2% and 42%) at 2 and 4 WPT and in 
esinophils (9% and 34.5%) but significant increase in 
neutrophils at 2 or 4 WPT (53.5% and 215.7%). Massoud 
et al. (2000) found non-significant change in total and 
differential leucocytic counts at 1,2,4 and 8 WPT with MZD 
in normal healthy rats orally in 3 dose levels 50,100 and 
200 mg/kg for 2 months. Waheeb and Abdel Hafeez
 
, 2001 
reported non-significant change in WBCs count and 
esinophils 2 months after treatment with MZD (15 mg/kg for 
3 days) in cases of intestinal schistosomiasis. 
In the current study, S.mansoni-infected non-treated 
mice showed progressive degree of thrombocytopenia (as 
the platelet count decreased in response to time of infection 
in rate of (14.1%, 20.7% and 33.6%) at 8,9 and 11 WPI, 
respectively as compared to the non-infected non-treated 
control mice .These results agreed with those of  Stanley et 
al.at 12 WPI and against what reported by El-Shenawy, 
2008 who found significant thrombocytosis (+107.1%) at 7 
WPI while Thabet et al. (2007)
 
reported non-significant 
change in platelet count in S.mansoni-infected mice at 
11WPI. Treatment with PZQ or MZD caused significant 
increase in the platelet count at 2 or 4 WPT and the effect 
was higher for PZQ (31.9% and 72.1%) followed by MZD 
(25.5% and 50.4%). This elevation in platelet counts may 
be due worm death and subsequently decrease in egg 
excretion depending on the potency of the drug. 
 
CONCLUSION 
This study declared that PZQ and MZD as 
antischistosomal drugs were highly safe without adverse 
haemtological effects on infected treated mice and PZQ 
showed more ameliorative effects than MZD.  
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